ACE and heart failure: For instance, several analyses have demonstrated that ACE inhibitors are cost-effective in the treatment of heart failure due to their proven efficacy and relatively lower cost compared to ARBs.[1,2] A notable study found that ACE inhibitors provided a cost-effective treatment option with an incremental cost-effectiveness ratio (ICER) well below commonly accepted willingness-to-pay (WTP) thresholds.